NIVOLUMAB (alone or when added to a regimen above) + PEMBROLIZUMAB (alone or when added to a regimen above) + Durvalumab + Trastuzumab
Phase 1Recruiting 1 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gastroesophageal Adenocarcinoma
Conditions
Gastroesophageal Adenocarcinoma
Trial Timeline
Jun 27, 2025 → Jun 1, 2027
NCT ID
NCT05733689About NIVOLUMAB (alone or when added to a regimen above) + PEMBROLIZUMAB (alone or when added to a regimen above) + Durvalumab + Trastuzumab
NIVOLUMAB (alone or when added to a regimen above) + PEMBROLIZUMAB (alone or when added to a regimen above) + Durvalumab + Trastuzumab is a phase 1 stage product being developed by BillionToOne for Gastroesophageal Adenocarcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05733689. Target conditions include Gastroesophageal Adenocarcinoma.
What happened to similar drugs?
3 of 20 similar drugs in Gastroesophageal Adenocarcinoma were approved
Approved (3) Terminated (1) Active (17)
Hype Score Breakdown
Clinical
6
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05733689 | Phase 1 | Recruiting |
Competing Products
20 competing products in Gastroesophageal Adenocarcinoma